This implies that passive immunization with tau antibodies can be a feasible therapeutic concentrate on and which the CSF degree of p-tau262/356 or in the microtubule binding domain (MTBD) can function a handy biomarker of tau pathology to watch tau therapeutics in clinical trials.To start with, they tested this technique on eighteen recognized bio